Russia Biotech HSCI To Launch Ischemia Drug By Month's End
This article was originally published in PharmAsia News
Executive Summary
Russian biotech Human Stem Cells Institute plans to launch by the end of the month its Neovasculgen for treating ischemia in the lower extremities, with plans to begin exports to neighboring countries, Europe and the U.S.